Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Intravenously Administered M6229 in Critically Ill Sepsis Patients - "HistoSeps"

NCT05208112 is registered in ClinicalTrials.gov with A.P.J. Vlaar as lead sponsor.

NCT NCT05208112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05208112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Intravenously Administered M6229 in Critically Ill Sepsis Patients - "HistoSeps"
Lead sponsor
A.P.J. Vlaar
Phase
Phase 1
Overall status
Completed
Start date
April 5, 2022
Completion date
September 28, 2023
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

critical illness, sepsis, septic shock